Literature DB >> 20708201

3T deep gray matter T2 hypointensity correlates with disability over time in stable relapsing-remitting multiple sclerosis: a 3-year pilot study.

Y Zhang1, L M Metz, V W Yong, J R Mitchell.   

Abstract

Abnormally decreased deep gray matter (GM) signal intensity on T2-weighted MRI (T2 hypointensity) is associated with brain atrophy and disability progression in patients with multiple sclerosis (MS) and is believed to represent excessive iron deposition. We investigated the time course of deep GM T2 hypointensity and its relationship with disability at 3T in 8 stable relapsing-remitting (RR) MS patients treated with minocycline over 3years. MRI and disability measurements were compared at baseline, 6, 12, 24, and 36months. Grand mean deep GM T2 hypointensity was negatively correlated with EDSS over time (r=-0.94, P=0.02). This correlation was strongest in the head of caudate (r=-0.95, P=0.01) and putamen (r=-0.89, P=0.04). Additionally, baseline grand mean deep GM T2 hypointensity appears to predict third year EDSS (r=-0.72, P=0.04). These results suggest that iron associated deep GM injury correlates with patient disability in stable RRMS. Measurements of deep GM T2 hypointensity at high field MRI may prove to be useful in monitoring individuals with MS. Further studies are required to confirm these results in a large sample and to determine if T2 hypointensity changes in clinically active MS patients. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20708201     DOI: 10.1016/j.jns.2010.07.014

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  7 in total

1.  Assessing abnormal iron content in the deep gray matter of patients with multiple sclerosis versus healthy controls.

Authors:  C A Habib; M Liu; N Bawany; J Garbern; I Krumbein; H-J Mentzel; J Reichenbach; C Magnano; R Zivadinov; E M Haacke
Journal:  AJNR Am J Neuroradiol       Date:  2011-11-24       Impact factor: 3.825

2.  Thalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis.

Authors:  A Burgetova; P Dusek; M Vaneckova; D Horakova; C Langkammer; J Krasensky; L Sobisek; P Matras; M Masek; Z Seidl
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-27       Impact factor: 3.825

3.  Basal Ganglia Iron in Patients with Multiple Sclerosis Measured with 7T Quantitative Susceptibility Mapping Correlates with Inhibitory Control.

Authors:  P Schmalbrock; R S Prakash; B Schirda; A Janssen; G K Yang; M Russell; M V Knopp; A Boster; J A Nicholas; M Racke; D Pitt
Journal:  AJNR Am J Neuroradiol       Date:  2015-11-26       Impact factor: 3.825

4.  Iron and neurodegeneration in multiple sclerosis.

Authors:  Michael Khalil; Charlotte Teunissen; Christian Langkammer
Journal:  Mult Scler Int       Date:  2011-02-10

Review 5.  Significance and In Vivo Detection of Iron-Laden Microglia in White Matter Multiple Sclerosis Lesions.

Authors:  Kelly M Gillen; Mayyan Mubarak; Thanh D Nguyen; David Pitt
Journal:  Front Immunol       Date:  2018-02-19       Impact factor: 7.561

6.  Deep Gray Matter Iron Content in Neuromyelitis Optica and Multiple Sclerosis.

Authors:  Adam Pudlac; Andrea Burgetova; Petr Dusek; Petra Nytrova; Manuela Vaneckova; Dana Horakova; Jan Krasensky; Lukas Lambert
Journal:  Biomed Res Int       Date:  2020-05-19       Impact factor: 3.411

7.  Early and Degressive Putamen Atrophy in Multiple Sclerosis.

Authors:  Julia Krämer; Sven G Meuth; Jan-Gerd Tenberge; Patrick Schiffler; Heinz Wiendl; Michael Deppe
Journal:  Int J Mol Sci       Date:  2015-09-25       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.